Advertisement

Macrolides: a clinical overview

  • Vito R. Iacoviello
  • Stephen H. Zinner
Chapter
Part of the Milestones in Drug Therapy MDT book series (MDT)

Abstract

The macrolide antibiotics have played an important role in the therapy of infectious diseases for many decades. Newer formulations have expanded the spectrum of activity, improved tissue penetration, and improved patient acceptance and compliance with reduced side effects and simpler, more convenient dosing regimens. In this chapter we will provide a brief review of some key clinical aspects of the macrolides, including spectrum of activity, emergence of resistance, clinical uses, tolerability and toxicity, pharmacologic considerations for the clinician, and the expanding data regarding the anti-inflammatory properties of the macrolides and their ability to modify selected bacterial virulence factors. Our comments will focus on erythromycin, clarithromycin, azithromycin, and roxithromycin.

Keywords

Acute Otitis Medium Typhoid Fever Neisseria Gonorrhoeae Macrolide Antibiotic Intrahepatic Cholestasis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Alvarez-Elcoro, S Enzler MJ (1999) The macrolides: erythromycin, clarithromycin, and azi-thromycin.Mayo Clin Proc 74: 613–634PubMedCrossRefGoogle Scholar
  2. 2.
    Erythromycin (2000) In:Physicians desk reference 54th edition. Medical Economics Co., Inc.,Montvale, NJ, 439–448Google Scholar
  3. 3.
    Clarithromycin (2000) In:Physicians desk reference 54th edition. Medical Economics Co., Inc.,Montvale, NJ, 409–417Google Scholar
  4. 4.
    Azithromycin (2000) In:Physicians desk reference 54th edition. Medical Economics Co., Inc.,Montvale, NJ, 2389–2399Google Scholar
  5. 5.
    Chia JK, Nakata MM, Lami JL, Park SS, Ding JC (1998) Azithromycin for the treatment of Cat-Scratch disease.Clin Infect Dis 26: 193–194PubMedCrossRefGoogle Scholar
  6. 6.
    Wiselka MJ, Read R, Finch RG (1996) Response to oral and intravenous azithromycin in a patient with toxoplasma encephalitis and AIDS.J Infect 33: 227–229PubMedCrossRefGoogle Scholar
  7. 7.
    Nasta P, Chiodera S (1997) Azithromycin for relapsing cerebral toxoplasmosis in AIDS.AIDS 11: 11–88CrossRefGoogle Scholar
  8. 8.
    Ramos JT, Saavedra J, Ruiz-Contreras J (1997) Cryptosporidium in patients infected with human immunodeficiency virus: azithromycin revisited.J Pediatr 130: 1009–1010PubMedCrossRefGoogle Scholar
  9. 9.
    Taylor WRJ, Richie TL, Fryauff DJ, Picarima H, Ohrt C, Tang D, Braitman D, Murphy GS, Widjaja H, Tjitra E et al (1999) Malaria prophylaxis using azithromycin: a double-blind, placebo-controlled trial in Irian Jaya, Indonesia.Clin Infect Dis 28: 74–81PubMedCrossRefGoogle Scholar
  10. 10.
    Hogue S, Weir A, Fluck R, Cunningham J (1996) Rhodococcus equi in CAPD-associated peritonitis treated with azithromycin.Nephrol Dial Transplant 11: 2340–2341CrossRefGoogle Scholar
  11. 11.
    Bryskier A (1998) Roxithromycin: review of its antimicrobial activity.J Antimicrob Chemother 41(Suppl. B): 1–21PubMedCrossRefGoogle Scholar
  12. 12.
    Uip DE, Lima AL, Amato VS, Boulos M, Neto VA, Bem David D (1998) Roxithromycin treatment of diarrhoea caused byCryptosporidium spp. in patients with AIDS.J Antimicrob Chemother 41(Suppl B): 93–97PubMedCrossRefGoogle Scholar
  13. 13.
    Durant J, Hazime F, Caries M, Pechere JC, Dellamonica P (1995) Prevention ofPneumocystis carinii pneumonia and of cerebral toxoplasmosis by roxithromycin in HIV-infected patients.Infection 23(Suppl 1): S33–S37PubMedCrossRefGoogle Scholar
  14. 14.
    Boswell FJ, Wise R (1998) Advances in the macrolides and quinolones.Infect Dis Clin North Am 12: 647–670PubMedCrossRefGoogle Scholar
  15. 15.
    Shortridge VD, Doern GV, Brueggmann AB, Beyer JM, Flamm RK (1999) Prevalence of macrolide resistance mechanisms inStreptococcus pneumoniae isolates from a multicenter antibiotic resistance surveillance study conducted in the United States in 1994–1995.Clin Infect Dis 29: 1186–1188PubMedCrossRefGoogle Scholar
  16. 16.
    Wiedemann BL (1998) Macrolides: clarithromycin and azithromycin.Pediatr Rev; 19: 238–239CrossRefGoogle Scholar
  17. 17.
    Hook EW, Stephens J, Ennis DM (1999) Azithromycin compared with penicillin G benzathine for treatment of incubating syphilis.Ann Int Med 131: 434–437PubMedGoogle Scholar
  18. 18.
    Morles CA, Hernandez I, Ferreiro MC (1997) Donovanosis: treatment with azithromycin.International J STD & AIDS 8: 54–56CrossRefGoogle Scholar
  19. 19.
    Meloni G, Meloni T (1996) Azithromycin vs. doxycycline for Mediterranean Spotted Fever.Pediatric Infect Dis J 15: 1042–1044CrossRefGoogle Scholar
  20. 20.
    Ferencz A (2000) Azithromycin in the therapy of ulceroglandular tularemia. In: SH Zinner, LS Young, JF Acar, C Ortiz-Neu (eds):New considerations for macrolides azalides streptogramins and ketolides. Marcel Dekker, Inc., New York, 376–381.Google Scholar
  21. 21.
    Elewski BE (2000) Pulse azithromycin is effective in inflammatory acne vulgaris. In: SH Zinner, LS Young, JF Acar, C Ortiz-Neu (eds):New considerations for macrolides azalides streptogramins and ketolides. Marcel Dekker, Inc., New York 362–366Google Scholar
  22. 22.
    Girgis NI, Brown FM, Tribble D, Butler T (2000) Randomized trial of azithromycin vs. ciprofloxacin for treatment of typhoid fever in Egypt. In: SH Zinner, LS Young, JF Acar, C Ortiz-Neu (eds):New considerations for macrolides azalides streptogramins,and ketolides. Marcel Dekker, Inc., New York, 336–340Google Scholar
  23. 23.
    Butler T, Sridhar CB, Daga MK, Pathak K, Pandit RB, Khakhria (2000) Treatment of typhoid fever in a randomized multicenter trial in India: a comparison of azithromycin and chloramphenicol. In: SH Zinner, LS Young, JF Acar, C Ortiz-Neu (eds):New considerations for macrolides azalides streptogramins and ketolides.: Marcel Dekker, Inc., New York, 341–347Google Scholar
  24. 24.
    Markham A, Faulds D (1994) Roxithromycin, an update of its antimicrobial activity, pharmacokinetic properties and therapeutic use.Drugs 48: 297–326PubMedCrossRefGoogle Scholar
  25. 25.
    Gurfinkel E, Bozovich G, Beck E, Testa E, Livellara B, Mautner B (1999) Treatment with the antibiotic roxithromycin in patients with acute non-Q-wave coronary syndromes. Eur Heart J 20: 121–127PubMedCrossRefGoogle Scholar
  26. 26.
    Tanaka M, Tao T, Kaku K, Kaneko T (1995) Agranulocytosis induced by macrolide antibiotics.Am J Hematol 48: 133PubMedGoogle Scholar
  27. 27.
    Anonymous (1999) Hypertrophic pyloric stenosis in infants following pertussis prophylaxis with erythromycin-Knoxville Tennessee, MMWR 1999; 48: 1117–1120Google Scholar
  28. 28.
    Longo G, Valenti C, Gandini G, Ferrara L, Bertesi M, Emilia G (1997) Azithromycin-induced intrahepatic cholestasis.Am J Med 102: 217–218PubMedGoogle Scholar
  29. 29.
    Begue P, Astruc J (1995) The overall safety of oral roxithromycin in paediatric clinical studies.Infection 23(Suppl 1): S25¡ªS27Google Scholar
  30. 30.
    Korzeniowski OM (2000) Macrolides, azalides, and streptogramins in patients with hepatic and renal failure. In: SH Zinner, LS Young, JF Acar, C Ortiz-Neu (eds):New considerations for macrolides azalides streptogramins,and ketolides. Marcel Dekker, Inc., New York, 45–52Google Scholar
  31. 31.
    Mole L (2000) Drug interactions with macrolides and related structures. In: SH Zinner, LS Young, JF Acar,C Ortiz-Neu(eds):New considerations for macrolides, azalides streptogramins and ketolides Marcel Dekker, Inc.,New York,25–34Google Scholar
  32. 32.
    Wales D, Woodhead M (1998) The anti-inflammatory effects of macrolides.Eur Respir J 12: 57–63CrossRefGoogle Scholar
  33. 33.
    Labro MT (1998) Anti-inflammatory activity of macrolides: a new therapeutic potential.J Antimicrob Chemother 41(Suppl B): 37–46PubMedCrossRefGoogle Scholar
  34. 34.
    Shryock TR, Mortensen JE, Baumholtz M (1998) The effects of macrolides on the expression of bacterial virulence mechanisms.J Antimicrob Chemother 41: 505–512PubMedCrossRefGoogle Scholar
  35. 35.
    Howe RA, Spencer RC (1997) Macrolides for the treatment ofPseudomonas aeruginosa infections.J Antimicrob Chemother; 40: 153–155PubMedCrossRefGoogle Scholar

Copyright information

© Springer Basel AG 2002

Authors and Affiliations

  • Vito R. Iacoviello
    • 1
  • Stephen H. Zinner
    • 1
  1. 1.Harvard Medical SchoolMount Auburn HospitalCambridgeUSA

Personalised recommendations